A highly immunogenic vaccine against A/H7N9 influenza virus

Vaccine
Weiping CaoSuryaprakash Sambhara

Abstract

Since the first case of human infection in March 2013, continued reports of H7N9 cases highlight a potential pandemic threat. Highly immunogenic vaccines to this virus are urgently needed to protect vulnerable populations who lack protective immunity. In this study, an egg- and adjuvant-independent adenoviral vector-based, hemagglutinin H7 subtype influenza vaccine (HAd-H7HA) demonstrated enhanced cell-mediated immunity as well as serum antibody responses in a mouse model. Most importantly, this vaccine provided complete protection against homologous A/H7N9 viral challenge suggesting its potential utility as a pandemic vaccine.

References

Feb 28, 2008·Molecular Therapy : the Journal of the American Society of Gene Therapy·Neetu SinghSuresh K Mittal
May 9, 2008·The Journal of Infectious Diseases·Mary A HoelscherSuryaprakash Sambhara
Apr 30, 2010·Expert Reviews in Molecular Medicine·Neetu SinghSuresh K Mittal
Jul 22, 2014·Trends in Immunology·Nicole L La Gruta, Stephen J Turner
Sep 13, 2014·Influenza and Other Respiratory Viruses·Kristy BlanchfieldIan A York
Feb 18, 2015·The Journal of Clinical Investigation·Carole J Henry DunandPatrick C Wilson
Jul 25, 2015·Epidemiology and Infection·W D TannerA V Gundlapalli

❮ Previous
Next ❯

Citations

May 24, 2017·Expert Review of Vaccines·Irina Isakova-Sivak, Larisa Rudenko

❮ Previous
Next ❯

Related Concepts

Related Feeds

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.